Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients

Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of immunopathology and pharmacology Jg. 25; H. 2; S. 475
Hauptverfasser: Riccio, A M, Dal Negro, R W, Micheletto, C, De Ferrari, L, Folli, C, Chiappori, A, Canonica, G W
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.04.2012
Schlagworte:
Adult
Anti-Asthmatic Agents - therapeutic use
Antibodies, Anti-Idiotypic - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Asthma - diagnosis
Asthma - drug therapy
Asthma - immunology
Asthma - pathology
Basement Membrane - drug effects
Basement Membrane - pathology
Biopsy
Bronchi - drug effects
Bronchi - immunology
Bronchi - pathology
Eosinophils - drug effects
Eosinophils - immunology
Female
Humans
Italy
Male
Middle Aged
Omalizumab
Respiratory Hypersensitivity - diagnosis
Respiratory Hypersensitivity - drug therapy
Respiratory Hypersensitivity - immunology
Respiratory Hypersensitivity - pathology
Severity of Illness Index
Time Factors
Treatment Outcome
Italy
ISSN:0394-6320
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0394-6320
DOI:10.1177/039463201202500217